Phase 3 study of adjunctive soticlestat in pediatric and young adult patients with Dravet syndrome

Phase 3, randomised, double-blind trial in Dravet syndrome comparing Soticlestat + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Percent change from baseline in convulsive seizure frequency per 28 days.